
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Charles River has announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Together they will launch multiple integrated programs across Takeda’s four core therapeutic areas with the ultimate goal of delivering preclinical candidates that Takeda can advance into clinical development.
For more information on this collaboration, click






